-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![q1 2024 results video thumbnail](https://volition.com/wp-content/uploads/2024/05/q1-2024-results-video-thumbnail.jpg)
VolitionRx Limited First Quarter 2024 Financial Results and Business Update
- Share
- Tweet
- Share on Facebook
- Share
![q1 2024 results video thumbnail](https://volition.com/wp-content/uploads/2024/05/q1-2024-results-video-thumbnail.jpg)
A short video to accompany the first quarter 2024 results for Volition with Group Chief Executive Officer, Cameron Reynolds, and Chief Financial Officer, Terig Hughes.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields